CN111020061A - Multiplex PCR primer group, kit and method for detecting HPV based on high-throughput sequencing - Google Patents
Multiplex PCR primer group, kit and method for detecting HPV based on high-throughput sequencing Download PDFInfo
- Publication number
- CN111020061A CN111020061A CN201911409567.3A CN201911409567A CN111020061A CN 111020061 A CN111020061 A CN 111020061A CN 201911409567 A CN201911409567 A CN 201911409567A CN 111020061 A CN111020061 A CN 111020061A
- Authority
- CN
- China
- Prior art keywords
- primer
- magnetic beads
- sample
- multiplex pcr
- hpv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a multiplex PCR primer group and a kit for detecting HPV based on high-throughput sequencing. The current methods are difficult to realize HPV high-throughput sample detection. When the requirement of detecting the sample size is large, a large amount of manpower is needed for operation. The method established by the invention can be used for amplifying and purifying by a one-step method, a library is established by the one-step method, and the method does not need to rotate the tube in the midway and open the cover, thereby effectively avoiding the confusion or cross contamination among samples; the library construction of 96 samples can be completed in 5 hours, the operation is simple and convenient, and the detection of a large number of samples can be easily realized. By increasing the number of sample tags in the adapter primers, the number of sample detections that can be performed in one sequencing run can be increased, further reducing the average manual time for a single sample.
Description
Technical Field
The invention belongs to the field of next-generation sequencing, and particularly relates to a multiple PCR primer set, a kit and a method for detecting HPV based on high-throughput sequencing.
Background
According to the statistical data of the world health organization in 2018, the cervical cancer is the fourth female malignant tumor worldwide, and about 57 ten thousand new cases are generated in 2018, and more than 31 ten thousand people die due to the cervical cancer. Worldwide, patients with cervical cancer are on the rise year by year and in a trend towards younger age. More than 10 ten thousand new cases in China are generated each year; the number of the diseases in other developing countries is more than 85 percent of the total number.
The cervical cancer is the only malignant tumor with definite etiology and capable of being prevented and cured in an early stage at present, 99.9 percent of cervical cancer is related to Human Papilloma Virus (HPV) infection, high-risk HPV persistent infection is an essential factor for the generation of the cervical cancer, and the risks caused by different types of HPV infection are different. Research shows that more than seven women have at least one HPV infection in one life, but most of HPV infections can be eliminated by the body's own immune system, and only 1% -4% of HPV infected people gradually develop lesions, which finally cause canceration. The world health organization recommends that cytological screening be performed every 3-5 years for women between the ages of 30 and 49 years, or HPV screening be performed every 5 years. Therefore, the key to the implementation of a normative and effective HPV screening strategy for cervical cancer prevention and treatment is realized.
High throughput sequencing, also known as massively parallel sequencing, or second generation sequencing. High-throughput sequencing, which can be performed by passing one sample through multiple target regions or multiple samples at a time, has also gained increasing attention in clinical applications, including pharmacogenomics, genetic disease research and screening, tumor mutation gene detection, and clinical microbial detection. The whole high-throughput sequencing process comprises the steps of nucleic acid extraction, library construction, sequencing, data analysis and the like of a sample. Firstly, before high-throughput sequencing, constructing a library for an extracted nucleic acid sample, namely, carrying a specific fragment which can be identified by a sequencer on the sample so as to facilitate template preparation of the sample, identification by the sequencer and sequencing; and secondly, a sample specificity label is carried on the sample to distinguish different samples, so that a plurality of samples can be sequenced at the same time, and the sequencing cost of the sample is reduced.
The main approaches to library construction today are hybrid capture and multiplex PCR.
Hybrid capture refers to the process of specific binding to a target region and then capture by designing a pool of probes that specifically recognize the target region. The hybrid capture process comprises: nucleic acid fragmentation-end repair-ligation and linker-amplification-pre-library purification-target region capture-library amplification-purification and the like. The library building method has long process, and the whole process needs more than 24 hours; the operation is complex, and the requirement on the capability of operators is high due to a plurality of fine steps. Therefore, hybrid capture is relatively difficult for library construction on large scale samples.
The multiplex PCR library building method is a scalable application of PCR technology. The operation flow of the currently used multiplex PCR library building method comprises the following steps: PCR, partial primer digestion, ligation and adapter addition, sample purification and the like. The operation is relatively simple, and the experimenter can master the method easily. However, in the operation process, one or more steps of uncovering exist after the PCR is finished so as to carry out subsequent operation, and a sample is easily polluted by environmental aerosol; meanwhile, aerosol generated after sample PCR may also pollute subsequent detection samples; in addition, the development of multiplex PCR is difficult, and in addition to the specificity of primers, the problems of primer mismatching and primer dimer formation need to be considered, and the more primers, the higher the possibility of forming mismatching or dimer.
In the operation process of hybridization or multiplex PCR, uncapping operation after tube rotation or PCR exists, and the possibility of cross contamination among samples exists; moreover, each sample requires a multi-step operation, which is complicated and difficult to handle with a large number of samples.
In light of the above problems, the present invention is directed to the study of a high throughput sequencing-based HPV detection method.
Disclosure of Invention
The invention aims to provide an HPV detection method based on high-throughput sequencing and application thereof, and solves the problems of easy sample pollution, inaccurate detection result, large sample amount and the like in the sample detection process by using a multiple PCR method.
The technical scheme adopted by the invention is as follows:
in the first aspect of the invention, a multiple PCR primer group for detecting HPV based on high-throughput sequencing is provided, wherein each multiple primer consists of a bridging sequence and specific sequences targeting different types of HPV; the bridging sequence matches with the adaptor primer; the specific sequences are as follows:
the nucleic acid sequence of the multiplex PCR primer group is numbered as follows: F001-F011 are numbered SEQ ID NO. 1-SEQ ID NO. 11; the numbers of R001-R012 are SEQ ID NO. 12-SEQ ID NO. 23.
In a second aspect of the invention, a kit for detecting HPV based on high-throughput sequencing is provided, which comprises the multiplex PCR primer set and the adapter primer.
According to the embodiment of the invention, the adaptor primer comprises the following components from 5 'end to 3' end in sequence: a sequencer related universal sequence, an 8bp sample tag sequence and a bridging sequence matched with the 5' end of the multiplex PCR primer.
According to the embodiment of the invention, the adaptor primer and the multiplex PCR primer are connected by matching bridging sequences, and the nucleotide sequences are as follows:
| name (R) | Primer sequence (5 '→ 3') |
| P5-01 | CAAGCAGAAGACGGCATACGAGATAACGTGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-02 | CAAGCAGAAGACGGCATACGAGATAAACATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-03 | CAAGCAGAAGACGGCATACGAGATATGCCTAAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-04 | CAAGCAGAAGACGGCATACGAGATAGTGGTCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-05 | CAAGCAGAAGACGGCATACGAGATACCACTGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-06 | CAAGCAGAAGACGGCATACGAGATACATTGGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-07 | CAAGCAGAAGACGGCATACGAGATCAGATCTGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P5-08 | CAAGCAGAAGACGGCATACGAGATCATCAAGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC |
| P7-01 | AATGATACGGCGACCACCGAGATCTACACAGATCGCAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-02 | AATGATACGGCGACCACCGAGATCTACACAGCAGGAAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-03 | AATGATACGGCGACCACCGAGATCTACACAGTCACTAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-04 | AATGATACGGCGACCACCGAGATCTACACATCCTGTAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-05 | AATGATACGGCGACCACCGAGATCTACACATTGAGGAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-06 | AATGATACGGCGACCACCGAGATCTACACCAACCACAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-07 | AATGATACGGCGACCACCGAGATCTACACGACTAGTAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-08 | AATGATACGGCGACCACCGAGATCTACACCAATGGAAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-09 | AATGATACGGCGACCACCGAGATCTACACCACTTCGAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-10 | AATGATACGGCGACCACCGAGATCTACACCAGCGTTAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-11 | AATGATACGGCGACCACCGAGATCTACACCATACCAAACACTCTTTCCCTACACGACGCTCTTCCGATC |
| P7-12 | AATGATACGGCGACCACCGAGATCTACACCCAGTTCAACACTCTTTCCCTACACGACGCTCTTCCGATC |
According to the embodiment of the invention, the 8bp tag sequence can be replaced by a different 8bp tag sequence or a sample tag of 6-12bp in the example, so as to increase the number of tags and further expand the detection amount of the sample.
According to an embodiment of the invention, the nucleic acid sequence is numbered: P5-01-P5-08 is numbered as SEQ ID NO. 24-SEQ ID NO. 31; P7-01-P7-12 are numbered as SEQ ID NO. 32-SEQ ID NO. 43.
In a second aspect of the present invention, a method for detecting HPV based on high throughput sequencing is provided, comprising the following steps: extracting sample genome DNA, carrying out PCR amplification reaction by using the primer group of claim 1 and the primer of claim 3, purifying the amplified product to construct a library, and sequencing to detect whether HPV nucleic acid exists in the sample.
According to an embodiment of the present invention, the nucleic acid sequence of the multiplex PCR primer sequence of the reference gene GADPH:
F-control CTGGAGTTCAGACGTGTGCTCTTCCGATCGCTTGCCCTGTCCAGTTA(SEQ IDNO.44)；
R-control TCTTTCCCTACACGACGCTCTTCCGATCTGCCAGGCTGGCCTGGCT(SEQ IDNO.45)。
according to the embodiment of the invention, the PCR amplification system is as follows:
| reagent | Final concentration |
| PCR Mix | 0.8～1.2× |
| Primer library | 0.2～5μM |
| Any P5 joint | 0.02～0.5μM |
| Any P7 joint | 0.02～0.5μM |
| DNA | Make up to 20. mu.L |
According to an embodiment of the present invention, the PCR amplification procedure is:
according to the embodiment of the invention, the multiple PCR primer groups are diluted to 50-200 mu M and then mixed into a primer library to carry out multiple PCR amplification reaction.
According to an embodiment of the present invention, the purification and construction of the library are performed as follows:
1) after the PCR reaction is finished, combining samples, and purifying and concentrating the samples to 30-100 mu L by using a nucleic acid purification kit;
2) adding 0.6-0.8 times volume of AMpure XP magnetic beads (capable of purifying nucleic acid or screening fragments), uniformly mixing, standing at room temperature for 2-5 min, putting on a magnetic frame, and washing with 150-200 mu L of fresh 70-80% ethanol for 2-3 times after the magnetic beads are completely adsorbed; after the magnetic beads are completely adsorbed, completely adsorbing residual ethanol by using a pipettor, drying at room temperature, adding 30-50 mu L of TE for elution, and standing at room temperature for 2-5 min;
3) transferring the supernatant to a new EP tube after the supernatant is adsorbed by the upper magnetic frame, adding equal volume of AMpure XP magnetic beads, uniformly mixing, standing at room temperature for 2-5 min, loading the supernatant on the magnetic frame, and after the magnetic beads are completely adsorbed, absorbing and discarding the supernatant; washing with 150-200 mu L of freshly prepared 70-80% ethanol for 2-3 times, centrifuging for a short time, then loading on a magnetic frame, completely adsorbing magnetic beads, completely adsorbing residual ethanol by using a pipettor, drying at room temperature, adding 20-50 mu L of TE for elution, and standing at room temperature for 2-5 min;
4) and (4) loading the magnetic rack, transferring the supernatant to a new EP tube after the magnetic beads are completely adsorbed, and obtaining the supernatant which is the required library.
The invention has the beneficial effects that:
the method adopts a tubular one-step method to complete library construction, and the library construction can be completed through one round of PCR; meanwhile, double-end sample labels are added to the corresponding libraries of each sample, so that different samples can be distinguished, and the samples are prevented from being interfered with each other. The coverage is wide, and up to 40 HPV types can be simultaneously detected. The specificity is strong, in the existing methodology, if the wind intensity of a certain HPV type is extremely high, the signals of the types with low abundance are covered, and the result interpretation is not accurate enough. According to the invention, the result is interpreted through second-generation sequencing, and each type of signal can be found, so that the result is more accurate. HPV is a very large item to be detected. The detection method has the advantages of multiple HPV types, high sensitivity, complete and accurate detection of all types of HPV covered and high cost of manpower and material resources.
The method established by the invention can complete library construction of 96 samples in 5 hours by one-step amplification and purification, is simple and convenient to operate, and can easily realize detection of a large number of samples. By increasing the number of sample tags in the adapter primer, the number of sample detections that can be performed in one sequencing run can be increased. For example, 96 samples can be detected at a time with 20 sample tags (8P 5 adapter primers + 12P 7 adapter primers); 384 samples can be detected if 40 sample tags (16P 5 adapter primers + 24P 7 adapter primers) are used at a time; if it is 60 sample tags (24P 5 adapter primers + 36P 7 adapter primers), 864 samples can be detected at a time, so the present invention can further reduce the average manual handling time of a single sample.
Drawings
FIG. 1 is a library quality control map in a clinical specimen identity test.
Detailed Description
In order to better illustrate the technical solution of the present invention, the following description is made with reference to the embodiments and the accompanying drawings, but not limited thereto.
Test materials:
QIAamp DNA Blood Mini Kit was purchased from Qiagen corporation management (Shanghai) Inc.; the nucleic acid purification kit is purchased from bio-engineering (Shanghai) GmbH; PCR Mix PlatinumTMMultiplex PCR MasterMix was purchased from Sammer Feishel technologies (China) Ltd, and AMpure XP magnetic beads were purchased from Beckmann Kulter trade (China) Ltd.
Example 1 primer design
Primer design comprises multiplex PCR primers and adapter primers.
The multiplex PCR primers contain specific sequences and bridging sequences. The specific sequences are designed aiming at 40 types of HPV, and are degenerated primers, and the annealing temperature is controlled at 58-62 ℃; the bridge sequence is a portion which is the same for all the forward primers or the reverse primers, and is mainly a portion which is combined with the bridge sequence of the adaptor primer, and the length of the bridge sequence is adjusted according to actual conditions.
The joint primer comprises the following components from the 5 'end to the 3' end in sequence: a sequencer-related universal sequence, an 8bp sample tag sequence, and a bridging sequence matched with the 5' end of the multiplex PCR primer. The sample tags of each adapter primer band are different, and the annealing temperature of the bridging sequence part is 68-72 ℃. The 8bp sample label in the adapter primer can be replaced to meet the requirement of large sample amount; the specific part of the internal reference primer is designed aiming at the GADPH gene of the human genome. The adaptor primer is connected with the multiplex PCR primer through the matching of the bridging sequence.
In the example, there are 23 PCR primers obtained by the above design method, the sequences of the primers are shown as SEQ ID No. 1-SEQ ID No.23, and the PCR primers are diluted to 100. mu.M before the test and mixed into a primer library at equal volume ratio.
20 adaptor primers, comprising 8P 5 sample tags and 12P 7 sample tags, as follows:
nucleotide sequence of internal reference gene:
F-control CTGGAGTTCAGACGTGTGCTCTTCCGATCGCTTGCCCTGTCCAGTTA(SEQ IDNO.44)；
R-control TCTTTCCCTACACGACGCTCTTCCGATCTGCCAGGCTGGCCTGGCT(SEQ IDNO.45)。
EXAMPLE 2 Artificial Synthesis of plasmid specificity and sensitivity test
Artificially synthesizing 7 plasmids: HPV16, HPV18, HPV31, HPV33, HPV35, HPV58, HPV 68. 3 test concentrations are set, 10 respectively5Copy/test, 103Copy/test, 102Copy/test. Three positive controls (all of HPV16, HPV18, HPV31, HPV33, HPV58, HPV35, HPV68 and other plasmid and human genome DNA mixture) are set: PC-1(200 copies/test), PC-2(1000 copies/test), PC-3(5000 copies/test), and one Negative Control (NC), for a total of 25 samples, with the adapter primer settings shown in Table 1:
TABLE 1 linker primer set-up
Preparing a PCR amplification reaction system:
| reagent | Final concentration |
| PCR Mix | 1× |
| Primer library | 0.5μM |
| Any P5 joint | 0.4μM |
| Any P7 joint | 0.4μM |
| DNA | Make up to 20. mu.L |
Setting a PCR amplification reaction program:
constructing a library:
1) after the PCR reaction is finished, merging samples, and purifying and concentrating the samples to 50 mu L by using a nucleic acid purification kit;
2) adding 35 μ L AMpure XP magnetic beads, mixing, standing at room temperature for 3min, loading on a magnetic rack, and washing with 150 μ L of freshly prepared 80% ethanol for 2 times after the magnetic beads are completely adsorbed; after the magnetic beads are completely adsorbed, completely adsorbing residual ethanol by using a pipettor, drying at room temperature, adding 30 mu L of TE for elution, and standing at room temperature for 2-5 min;
3) transferring the supernatant to a new EP tube after adsorption by a magnetic frame, adding 30 mu L AMpure XP magnetic beads, uniformly mixing, standing at room temperature for 3min, loading the supernatant on the magnetic frame, and after the magnetic beads are completely adsorbed, absorbing and discarding the supernatant; washing with 150 μ L of freshly prepared 80% ethanol for 2 times, centrifuging for a short time, loading onto magnetic frame, completely adsorbing magnetic beads, removing residual ethanol with pipette, drying at room temperature, eluting with 30 μ L of TE, and standing at room temperature for 3 min;
4) and (4) loading the magnetic rack, transferring the supernatant to a new EP tube after the magnetic beads are completely adsorbed, and obtaining the supernatant which is the required library.
Sequencing by using an Illumina MiniSeq medium flux sequencing kit, wherein the sequencing data cluster density is 148K/mm2The cluster passage rate was 82.7% and Q30 was 90.8%, actually yielding 0.6M reads.
And (4) analyzing results: the results are shown in Table 2, all types of the three positive samples have reads, and the number of the reads of the negative samples is 0; of the 21 samples, there was good specificity and exhibited good gradient effect; can be detected for 100 copies of the plasmid.
Table 2 results of each sample after data analysis
Note: + indicates positive; negative is indicated.
Example 3 clinical sample conformance testing
Taking 92 clinical cervical swab samples, detecting the samples to be positive HPV by a fluorescence PCR method, extracting genomic DNA by using a QIAamp DNAbood mini kit, performing 1 test on each sample, performing 92 tests in total, and sequentially marking the samples as 1-92 samples; three positive controls, PC-1(200 copies/test), PC-2(1000 copies/test), PC-3(5000 copies/test), and one Negative Control (NC), were set up for 96 samples. The assay was completed in a 96-well plate with the adapter primer set as shown in table 3:
TABLE 3 linker primer set-up
Preparing a PCR amplification reaction system:
| reagent | Final concentration |
| PCR Mix | 1× |
| Primer library | 0.5μM |
| Any P5 joint | 0.4μM |
| Any P7 joint | 0.4μM |
| DNA | Make up to 20. mu.L |
Setting a PCR amplification reaction program:
constructing a library:
1) after the PCR reaction is finished, merging samples, and purifying and concentrating the samples to 50 mu L by using a nucleic acid purification kit;
2) adding 35 μ L AMpure XP magnetic beads, mixing, standing at room temperature for 3min, loading on a magnetic rack, and washing with 150 μ L of freshly prepared 80% ethanol for 2 times after the magnetic beads are completely adsorbed; after the magnetic beads are completely adsorbed, completely adsorbing residual ethanol by using a pipettor, drying at room temperature, adding 30 mu L of TE for elution, and standing at room temperature for 2-5 min;
3) transferring the supernatant to a new EP tube after adsorption by a magnetic frame, adding 30 mu L AMpure XP magnetic beads, uniformly mixing, standing at room temperature for 3min, loading the supernatant on the magnetic frame, and after the magnetic beads are completely adsorbed, absorbing and discarding the supernatant; washing with 150 μ L of freshly prepared 80% ethanol for 2 times, centrifuging for a short time, loading onto magnetic frame, completely adsorbing magnetic beads, removing residual ethanol with pipette, drying at room temperature, eluting with 30 μ L of TE, and standing at room temperature for 3 min;
4) and (4) loading the magnetic rack, transferring the supernatant to a new EP tube after the magnetic beads are completely adsorbed, and obtaining the supernatant which is the required library.
The purified library was subjected to quality inspection using Perkin Elmer LabChip GX Touch HT, and the results are shown in FIG. 1.
Sequencing by using an Illumina MiniSeq medium flux sequencing kit, wherein the sequencing data cluster density is 110K/mm2The cluster passage was 95.2% and Q30 was 96.7%, yielding 1.9M reads.
And (4) analyzing results: as shown in Table 4, the results of this experiment showed good agreement with the fluorescent PCR method. In 1 of the samples (sample 43), the NGS method of this patent showed less type 81 positivity. In 7 cases (samples 46,48,49,51,52,57,81), the NGS method showed more significant positive detection of HPV types on the basis of the detection of the same results as the PCR method.
TABLE 4 PCR assay and NGS assay results
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
SEQUENCE LISTING
<110> Guangzhou Mijing Gene medicine science and technology Co., Ltd
<120> HPV detection multiplex PCR primer set, kit and method based on high-throughput sequencing
<130>
<160>45
<170>PatentIn version 3.5
<210>1
<211>49
<212>DNA
<213> Artificial sequence
<400>1
ctggagttca gacgtgtgct cttccgatcg caacgtgcmc arggccata 49
<210>2
<211>52
<212>DNA
<213> Artificial sequence
<400>2
ctggagttca gacgtgtgct cttccgatcc tacarcgtgc acaaggtcat aa 52
<210>3
<211>51
<212>DNA
<213> Artificial sequence
<400>3
ctggagttca gacgtgtgct cttccgatct acaacgkgca cagggycata a 51
<210>4
<211>51
<212>DNA
<213> Artificial sequence
<400>4
ctggagttca gacgtgtgct cttccgatct tacaacgwgc rcarggmcac a 51
<210>5
<211>51
<212>DNA
<213> Artificial sequence
<400>5
ctggagttca gacgtgtgct cttccgatct gcawcgtgcy cagggacaya a 51
<210>6
<211>51
<212>DNA
<213> Artificial sequence
<400>6
ctggagttca gacgtgtgct cttccgatcc tscamcgtgc scagggycac a 51
<210>7
<211>52
<212>DNA
<213> Artificial sequence
<400>7
ctggagttca gacgtgtgct cttccgatcc tscaccgtmg scagggycac aa 52
<210>8
<211>48
<212>DNA
<213> Artificial sequence
<400>8
ctggagttca gacgtgtgct cttccgatcc awarggcrca gggycaya 48
<210>9
<211>50
<212>DNA
<213> Artificial sequence
<400>9
ctggagttca gacgtgtgct cttccgatca cataaggccc agggccayaa 50
<210>10
<211>50
<212>DNA
<213> Artificial sequence
<400>10
ctggagttca gacgtgtgct cttccgatct acaaaargcc cagggmcata 50
<210>11
<211>52
<212>DNA
<213> Artificial sequence
<400>11
ctggagttca gacgtgtgct cttccgatcc tkcamaaggc acagggayah aa 52
<210>12
<211>59
<212>DNA
<213> Artificial sequence
<400>12
tctttcccta cacgacgctc ttccgatcta aatrgmcggg rtcatasyat gaatatatg 59
<210>13
<211>60
<212>DNA
<213> Artificial sequence
<400>13
tctttcccta cacgacgctc ttccgatctc aaaatagtgg yatycatmtt atgaatgtat 60
<210>14
<211>61
<212>DNA
<213> Artificial sequence
<400>14
tctttcccta cacgacgctc ttccgatctc aaaataktgg aattcataga atgtatrtat 60
g 61
<210>15
<211>59
<212>DNA
<213> Artificial sequence
<400>15
tctttcccta cacgacgctc ttccgatcta ayaaygtrgg atccatwgca tgaatatat 59
<210>16
<211>59
<212>DNA
<213> Artificial sequence
<400>16
tctttcccta cacgacgctc ttccgatcta watrytrsta ttcataytrt gdatatakg 59
<210>17
<211>61
<212>DNA
<213> Artificial sequence
<400>17
tctttcccta cacgacgctc ttccgatctc aaaatagcag gattcatast rtgwatatat 60
g 61
<210>18
<211>60
<212>DNA
<213> Artificial sequence
<400>18
tctttcccta cacgacgctc ttccgatctc aaaacagarg gattcattgt gtgawtatag 60
<210>19
<211>60
<212>DNA
<213> Artificial sequence
<400>19
tctttcccta cacgacgctc ttccgatcta atatasmrgv attcatartr tgaadatarg 60
<210>20
<211>59
<212>DNA
<213> Artificial sequence
<400>20
tctttcccta cacgacgctc ttccgatcta raatkgtagr atccatkgtg tgyarataa 59
<210>21
<211>61
<212>DNA
<213> Artificial sequence
<400>21
tctttcccta cacgacgctc ttccgatctc agtargktag mattcatakt atgtaaatak 60
g 61
<210>22
<211>59
<212>DNA
<213> Artificial sequence
<400>22
tctttcccta cacgacgctc ttccgatcta ataaakkwtt attcatayta tgyarrtat 59
<210>23
<211>58
<212>DNA
<213> Artificial sequence
<400>23
tctttcccta cacgacgctc ttccgatcta yadkgmstta ttcatawtat gtadgtar 58
<210>24
<211>65
<212>DNA
<213> Artificial sequence
<400>24
caagcagaag acggcatacg agataacgtg atgtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>25
<211>65
<212>DNA
<213> Artificial sequence
<400>25
caagcagaag acggcatacg agataaacat cggtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>26
<211>65
<212>DNA
<213> Artificial sequence
<400>26
caagcagaag acggcatacg agatatgcct aagtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>27
<211>65
<212>DNA
<213> Artificial sequence
<400>27
caagcagaag acggcatacg agatagtggt cagtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>28
<211>65
<212>DNA
<213> Artificial sequence
<400>28
caagcagaag acggcatacg agataccact gtgtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>29
<211>65
<212>DNA
<213> Artificial sequence
<400>29
caagcagaag acggcatacg agatacattg gcgtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>30
<211>65
<212>DNA
<213> Artificial sequence
<400>30
caagcagaag acggcatacg agatcagatc tggtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>31
<211>65
<212>DNA
<213> Artificial sequence
<400>31
caagcagaag acggcatacg agatcatcaa gtgtgactgg agttcagacg tgtgctcttc 60
cgatc 65
<210>32
<211>69
<212>DNA
<213> Artificial sequence
<400>32
aatgatacgg cgaccaccga gatctacaca gatcgcaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>33
<211>69
<212>DNA
<213> Artificial sequence
<400>33
aatgatacgg cgaccaccga gatctacaca gcaggaaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>34
<211>69
<212>DNA
<213> Artificial sequence
<400>34
aatgatacgg cgaccaccga gatctacaca gtcactaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>35
<211>69
<212>DNA
<213> Artificial sequence
<400>35
aatgatacgg cgaccaccga gatctacaca tcctgtaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>36
<211>69
<212>DNA
<213> Artificial sequence
<400>36
aatgatacgg cgaccaccga gatctacaca ttgaggaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>37
<211>69
<212>DNA
<213> Artificial sequence
<400>37
aatgatacgg cgaccaccga gatctacacc aaccacaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>38
<211>69
<212>DNA
<213> Artificial sequence
<400>38
aatgatacgg cgaccaccga gatctacacg actagtaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>39
<211>69
<212>DNA
<213> Artificial sequence
<400>39
aatgatacgg cgaccaccga gatctacacc aatggaaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>40
<211>69
<212>DNA
<213> Artificial sequence
<400>40
aatgatacgg cgaccaccga gatctacacc acttcgaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>41
<211>69
<212>DNA
<213> Artificial sequence
<400>41
aatgatacgg cgaccaccga gatctacacc agcgttaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>42
<211>69
<212>DNA
<213> Artificial sequence
<400>42
aatgatacgg cgaccaccga gatctacacc ataccaaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>43
<211>69
<212>DNA
<213> Artificial sequence
<400>43
aatgatacgg cgaccaccga gatctacacc cagttcaaca ctctttccct acacgacgct 60
cttccgatc 69
<210>44
<211>47
<212>DNA
<213> Artificial sequence
<400>44
ctggagttca gacgtgtgct cttccgatcg cttgccctgt ccagtta 47
<210>45
<211>46
<212>DNA
<213> Artificial sequence
<400>45
tctttcccta cacgacgctc ttccgatctg ccaggctggc ctggct 46
Claims (8)
1. The multiplex PCR primer group for detecting HPV based on high-throughput sequencing is characterized in that each multiplex primer consists of a bridging sequence and a specific sequence targeting different types of HPV; the bridging sequence matches with the adaptor primer; the specific sequences are as follows:
。
2. A kit for detecting HPV multiplex PCR based on high-throughput sequencing, which is characterized by comprising the multiplex PCR primer set and the joint primer of claim 1.
3. The kit of claim 2, wherein the adaptor primer is, in order from 5 'to 3': universal sequences, sample tag sequences, and bridging sequences that match the 5' ends of the multiplex PCR primers.
4. A method for detecting HPV kit based on high-throughput sequencing is characterized by comprising the following steps: extracting sample genome DNA, carrying out PCR amplification reaction by using the multiplex PCR primer group and the adaptor primer as described in claim 1, purifying the amplification product, namely the constructed library, and determining the HPV type in the sample through sequencing and data analysis.
5. The method of claim 4, wherein the PCR amplification reaction system is:
6. the method of claim 4, wherein the PCR amplification procedure is:
7. the method according to claim 4, wherein the multiplex PCR primer set is diluted to 50-200. mu.M and then mixed into a primer library to perform the multiplex PCR amplification reaction.
8. The method of claim 4, wherein the purification and library construction steps are as follows:
1) after PCR reaction, merging samples, and concentrating to 30-100 mu L;
2) adding 0.6-0.8 times of AMpure XP magnetic beads, mixing uniformly, adsorbing the magnetic beads until the solution is clarified, discarding the supernatant, retaining the magnetic beads, adding ethanol, adsorbing the magnetic beads until the solution is clarified, volatilizing the ethanol, retaining the magnetic beads, and eluting with TE;
3) transferring the supernatant to a new EP tube, adding an AMpure XP magnetic bead with the same volume,
4) mixing, adsorbing magnetic beads until the solution is clear, discarding the supernatant, retaining the magnetic beads, adding ethanol, adsorbing the magnetic beads until the solution is clear, volatilizing the ethanol, adding TE for elution, adsorbing the magnetic beads until the solution is clear, and obtaining the supernatant as a library.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911409567.3A CN111020061B (en) | 2019-12-31 | 2019-12-31 | Multiplex PCR primer group, kit and method for detecting HPV based on high-throughput sequencing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911409567.3A CN111020061B (en) | 2019-12-31 | 2019-12-31 | Multiplex PCR primer group, kit and method for detecting HPV based on high-throughput sequencing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111020061A true CN111020061A (en) | 2020-04-17 |
| CN111020061B CN111020061B (en) | 2021-01-05 |
Family
ID=70197482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911409567.3A Active CN111020061B (en) | 2019-12-31 | 2019-12-31 | Multiplex PCR primer group, kit and method for detecting HPV based on high-throughput sequencing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111020061B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111455114A (en) * | 2020-05-22 | 2020-07-28 | 深圳华大智造科技有限公司 | High-flux detection kit for SARS-CoV-2 |
| CN112029842A (en) * | 2020-08-31 | 2020-12-04 | 深圳市血液中心(深圳市输血医学研究所) | Kit and method for ABO blood type genotyping based on high-throughput sequencing |
| CN112251501A (en) * | 2020-10-28 | 2021-01-22 | 深圳人体密码基因科技有限公司 | Reference gene set and screening method thereof, universal primer group, kit, reaction system and application |
| CN112458195A (en) * | 2020-12-28 | 2021-03-09 | 广州迈景基因医学科技有限公司 | Multiplex PCR primer set, kit and method for detecting sexually transmitted pathogens based on high-throughput sequencing |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104561372A (en) * | 2014-12-11 | 2015-04-29 | 南京普东兴生物科技有限公司 | Combined primer for amplification and typing of human papilloma virogenes and application of combined primer |
| CN107988372A (en) * | 2018-01-03 | 2018-05-04 | 杭州联川基因诊断技术有限公司 | A kind of kit and its detection method for detecting susceptibility gene of colorectal cancer mutation |
| CN108728578A (en) * | 2018-06-12 | 2018-11-02 | 苏州国科闻普生物科技有限公司 | Detect the method and kit of a variety of high-risk human mammilla papillomavirus and its hypotype simultaneously in single tube reaction |
| CN109517885A (en) * | 2018-12-27 | 2019-03-26 | 北京迈基诺基因科技股份有限公司 | A kind of method and its primer special group based on high-flux sequence detection mouse DNA TCR beta chain immune group library |
| WO2019074960A1 (en) * | 2017-10-09 | 2019-04-18 | uBiome, Inc. | Single molecule sequencing and unique molecular identifiers to characterize nucleic acid sequences |
| CN110093454A (en) * | 2019-04-24 | 2019-08-06 | 南京格致医学检验有限公司 | The amplification sequencing approach analyzed for a variety of HPV Classification Identifications and genome conformity |
| CN110592200A (en) * | 2019-09-25 | 2019-12-20 | 人和未来生物科技（长沙）有限公司 | Multiplex PCR method for improving amplification specificity and uniformity |
-
2019
- 2019-12-31 CN CN201911409567.3A patent/CN111020061B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104561372A (en) * | 2014-12-11 | 2015-04-29 | 南京普东兴生物科技有限公司 | Combined primer for amplification and typing of human papilloma virogenes and application of combined primer |
| WO2019074960A1 (en) * | 2017-10-09 | 2019-04-18 | uBiome, Inc. | Single molecule sequencing and unique molecular identifiers to characterize nucleic acid sequences |
| CN107988372A (en) * | 2018-01-03 | 2018-05-04 | 杭州联川基因诊断技术有限公司 | A kind of kit and its detection method for detecting susceptibility gene of colorectal cancer mutation |
| CN108728578A (en) * | 2018-06-12 | 2018-11-02 | 苏州国科闻普生物科技有限公司 | Detect the method and kit of a variety of high-risk human mammilla papillomavirus and its hypotype simultaneously in single tube reaction |
| CN109517885A (en) * | 2018-12-27 | 2019-03-26 | 北京迈基诺基因科技股份有限公司 | A kind of method and its primer special group based on high-flux sequence detection mouse DNA TCR beta chain immune group library |
| CN110093454A (en) * | 2019-04-24 | 2019-08-06 | 南京格致医学检验有限公司 | The amplification sequencing approach analyzed for a variety of HPV Classification Identifications and genome conformity |
| CN110592200A (en) * | 2019-09-25 | 2019-12-20 | 人和未来生物科技（长沙）有限公司 | Multiplex PCR method for improving amplification specificity and uniformity |
Non-Patent Citations (5)
| Title |
|---|
| FREDERICO O. GLEBER-NETTO等: "Distinct Pattern of TP53 Mutations in Human Immunodeficiency Virus–Related Head and Neck Squamous Cell Carcinoma", 《CANCER CYTOPATHOL》 * |
| KENTA SHIRASAWA等: "Analytical workflow of double-digest restriction site-associated DNA sequencing based on empirical and in silico optimization in tomato", 《DNA RESEARCH》 * |
| 吴文苑等: "多重PCR法和HPV分型基因芯片法在高危型人***瘤病毒感染检测中的应用", 《国际检验医学杂志》 * |
| 曾凡杞等: "单管多重PCR鉴定HPV基因型方法的建立和临床评价", 《咸宁学院学报（医学版）》 * |
| 谢旺凯等: "***组织高危型HPV新分型检测方法的建立及应用", 《肿瘤学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111455114A (en) * | 2020-05-22 | 2020-07-28 | 深圳华大智造科技有限公司 | High-flux detection kit for SARS-CoV-2 |
| CN111455114B (en) * | 2020-05-22 | 2023-09-05 | 深圳华大智造科技股份有限公司 | High flux detection kit for SARS-CoV-2 |
| CN112029842A (en) * | 2020-08-31 | 2020-12-04 | 深圳市血液中心(深圳市输血医学研究所) | Kit and method for ABO blood type genotyping based on high-throughput sequencing |
| CN112029842B (en) * | 2020-08-31 | 2021-04-27 | 深圳市血液中心(深圳市输血医学研究所) | Kit and method for ABO blood type genotyping based on high-throughput sequencing |
| CN112251501A (en) * | 2020-10-28 | 2021-01-22 | 深圳人体密码基因科技有限公司 | Reference gene set and screening method thereof, universal primer group, kit, reaction system and application |
| CN112458195A (en) * | 2020-12-28 | 2021-03-09 | 广州迈景基因医学科技有限公司 | Multiplex PCR primer set, kit and method for detecting sexually transmitted pathogens based on high-throughput sequencing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111020061B (en) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111020061B (en) | Multiplex PCR primer group, kit and method for detecting HPV based on high-throughput sequencing | |
| US20080213870A1 (en) | Methods for obtaining modified DNA from a biological specimen | |
| CN101142323A (en) | Detection of human papilloma virus | |
| CN112391477B (en) | Method and device for detecting instability of free nucleic acid microsatellite | |
| CN114317762B (en) | Three-marker composition for detecting early liver cancer and kit thereof | |
| CN110468240B (en) | Method for rapidly acquiring multiple biological information from biological sample | |
| CN108546785B (en) | Method for detecting DNA of pathogenic microorganisms in genital tract | |
| CN104928399A (en) | Primer group, kit and use thereof in HPV whole-genome detection | |
| CN110241212B (en) | Primer set for sequencing and detecting BRCA1 and BRCA2 gene amplicons and application thereof | |
| CN116144811B (en) | Multiplex primer set, method and kit for detecting cerebrospinal fluid pathogen | |
| CN114214416B (en) | Biomarkers associated with pre-cervical lesion occurrence and uses thereof | |
| CN110734982A (en) | High-throughput sequencing technology-based linkage autosomal STR typing system and kit | |
| KR101401940B1 (en) | Kit for analyzing high-risk HPV gene and method for analyzing the same | |
| CN111443065A (en) | Lung cancer screening kit | |
| CN104561349A (en) | Method for flexibly detecting human papilloma virus genotypes in broad spectrum | |
| CN108300778A (en) | A kind of ventricular fibrillation gene differential diagnosis kit | |
| CN107937510A (en) | A kind of familial deterioration property atrioventricular block gene diagnosis kit | |
| CN113278688A (en) | Primer combination and kit for detecting HPV integration gene locus | |
| Oh et al. | Improved DNA extraction method for molecular diagnosis from smaller numbers of cells | |
| CN114657248B (en) | Plasma free DNA methylation biomarker for detecting early colorectal cancer or composition, application and kit thereof | |
| CN111455045B (en) | Diagnostic reagent for systemic lupus erythematosus and platform and application thereof | |
| CN114438261B (en) | Primer group and method for detecting goose astrovirus and goose tembusu virus | |
| CN112195286B (en) | Probe for detecting human papilloma virus HPV26 and kit thereof | |
| CN114395626B (en) | Marker for cervical cancer screening, probe composition and application thereof | |
| CN114369664B (en) | Marker for pancreatic cancer screening, probe composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cai Xingsheng Inventor after: Wang Chunlin Inventor after: Li Mengzhen Inventor after: Deng Yangyang Inventor after: Ma Zhihai Inventor after: Qian Dongyuan Inventor after: Liu Yasi Inventor after: Yue Xiaoyan Inventor after: Yang Dongcheng Inventor before: Cai Xingsheng Inventor before: Li Mengzhen Inventor before: Deng Yangyang Inventor before: Wang Chunlin Inventor before: Ma Zhihai Inventor before: Qian Dongyuan Inventor before: Liu Yasi Inventor before: Yue Xiaoyan Inventor before: Yang Dongcheng |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |